Improving Muscle Function in Nutritionally at Risk, Elderly Patients

Withdrawn before enrolling · Not applicable

Conditions studied: Muscle Weakness, ICU-acquired Weakness

In brief

The investigators propose to conduct a randomized, control trial of β-hydroxy-β-methylbutyrate (HMB) supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by ICU-specific nutritional risk scores. Patients will receive either 3g of HMB daily, or control, daily until day 28 following randomization (even if discharged).The investigators will measure functional outcomes using standard, validated measures prior and after discharge.

Key facts

Study ID

NCT03071354

Run by

Wake Forest University Health Sciences

People needed

0

Starts

2017-05-01

Expected to finish

2017-05-22

Last updated by the study team

2018-02-05

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age ≥65 years.
• Acute respiratory failure (ARF, defined by expected mechanical ventilation for > 72 hours from the point of screening)
• Elevated nutritional risk (NUTRIC score>5 - see below).

You may not qualify if…

• Over 72 hours from ICU admission.
• Not expected to survive another 48 hours
• Lack of commitment to full, aggressive care
• Patients who have an absolute contraindication to EN (obstruction, perforation, high output fistula),
• Pregnant women
• Prisoners
• Known allergy to study nutrients
• Unable to walk prior to current illness.

Where it is running

• Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.